301 related articles for article (PubMed ID: 15335406)
1. Review article: future indications for terlipressin therapy.
Lebrec D
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():65-7; discussion 68. PubMed ID: 15335406
[TBL] [Abstract][Full Text] [Related]
2. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
4. Review article: pharmacological treatment of hepatorenal syndrome.
Ginès P; Torre A; Terra C; Guevara M
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
[TBL] [Abstract][Full Text] [Related]
5. Terlipressin in hepatorenal syndrome.
Mazur JE; Cooper TB; Dasta JF
Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
[TBL] [Abstract][Full Text] [Related]
6. Terlipressin and albumin combination treatment in hepatorenal syndrome.
Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
9. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin. Type I hepatorenal syndrome: an extra window of time before liver transplantation.
Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17171813
[TBL] [Abstract][Full Text] [Related]
11. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.
Saner FH; Canbay A; Gerken G; Broelsch CE
Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):207-17. PubMed ID: 19072411
[TBL] [Abstract][Full Text] [Related]
13. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
Alessandria C; Ottobrelli A; Debernardi-Venon W; Todros L; Cerenzia MT; Martini S; Balzola F; Morgando A; Rizzetto M; Marzano A
J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
[TBL] [Abstract][Full Text] [Related]
14. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Ganne-Carrié N; Hadengue A; Mathurin P; Durand F; Erlinger S; Benhamou JP
Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
Caraceni P; Santi L; Mirici F; Montanari G; Bevilacqua V; Pinna AD; Bernardi M
Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
Singh V; Kumar R; Nain CK; Singh B; Sharma AK
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
[TBL] [Abstract][Full Text] [Related]
19. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
20. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
Halimi C; Bonnard P; Bernard B; Mathurin P; Mofredj A; di Martino V; Demontis R; Henry-Biabaud E; Fievet P; Opolon P; Poynard T; Cadranel JF
Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
